Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight
BioCardia Inc BCDA
$0.82
▲ +6.89%
(+$0.05)
🎈 Low Float
🗓️ Earnings Next Week
Open
$0.79
Prev Close
$0.77
Day Range
$0.79 – $0.82
52W Range
$0.75 – $2.29
Market Cap
$12.27M
Beta
0.48
EPS (TTM)
$-0.80
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1996-11-13 |
| Shares Out. | 14,880,000 |
| Website | biocardia.com/ ↗ |
| Phone | 13026587581 |
| Employees | 21 |
| Net Income | -$2.3M |
| Free Cash Flow | -$7.5M |
| Total Assets | $1.7M |
| Total Liabilities | $2.8M |
| Equity | -$1.1M |
About BioCardia Inc
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
BioCardia Inc is a publicly traded company under the ticker symbol BCDA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)